AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04440085 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: All patients become standard care resuscitation treatment using liquids and vasoactive drugs in order to get a median arterial pressure ≥ 65 mmHg. Placebo will be administered according to the evolution of the patient's mean pressure.
Study NCT01755260 — intervention group
Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Jejunostomy tube feeding
Description: The patients at this arm receive the nutritional support through the feeding jejunostomy tube; they can only eat or sip water through mouth
Study NCT01705886 — intervention group
Intervention type: PROCEDURE
Intervention: Total Knee Arthroplasty
Description: Patients undergoing manual (no robot used) surgery to replace of all 3 compartments of the knee
Study NCT01705886 — intervention group
Intervention type: PROCEDURE
Intervention: MAKO® Robot Assisted Medial Knee Arthroplasty
Description: Patients undergoing a MAKO® robot assisted surgery to replace the medial compartment of the knee
Study NCT01794208 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Follitropin Alfa
Study NCT02428751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated liposomal doxorubicin
Description: 30 mg/m2, IV (in the vein) on day 1 of each 21 day cycle
Study NCT02428751 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: 50 mg/m2, IV (in the vein) on day 1 of each 21 day cycle
Study NCT02428751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m2, IV (in the vein) on day 0 of each 21 day cycle
Study NCT02428751 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: 375 mg/m2, IV (in the vein) on day 0 of each 21 day cycle
Study NCT02428751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophophamide
Description: 750 mg/m2, IV (in the vein) on day 1 of each 21 day cycle
Study NCT02428751 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophophamide
Description: 750 mg/m2, IV (in the vein) on day 1 of each 21 day cycle
Study NCT02428751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: 1.4 mg/m2 (2mg in maxium), IV (in the vein) on day 1 of each 21 day cycle
Study NCT02428751 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine
Description: 1.4 mg/m2 (2mg in maxium), IV (in the vein) on day 1 of each 21 day cycle
Study NCT02428751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 100mg/d, PO on day 1-5 of each 21 day cycle
Study NCT02428751 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: 100mg/d, PO on day 1-5 of each 21 day cycle
Study NCT03990623 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Computed Tomography Perfusion Imaging
Description: Undergo perfusion CT
Study NCT03990623 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liver Biopsy
Description: Undergo liver biopsy
Study NCT04208386 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-73763989
Description: JNJ-73763989 will be administered SC under fasted condition.
Study NCT03755674 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CHRONOTYPE-ADJUSTED DIET
Description: Those patients followed a daily caloric distribution attending to their chronotype. In this regards, 'morning' subjects ate a higher quantity of calories at the first part of the day, while 'evening' subjects ate a higher amount of calories at the second half of the day.
Study NCT02458131 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TEEN HEED
Description: Peer-led workshops will cover behavioral skills including goal setting, self-monitoring, problem solving, contingency management, coping skills, and social support.
Study NCT00526656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib malate
Description: 50mg PO daily 4 weeks on -2 weeks off
Study NCT01311115 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group commitment contract
Description: 1. Each participant is required to deposit at least 50 baht at enrollment. A deposit collector visits each participant on a weekly basis and collects additional deposits on a voluntary basis. All deposits are returned only if the smoker quits successfully within three months.~2. The project gives a matching contribution of 150 baht for the initial deposit of at least 50 baht. All participants in the treatment group are further randomized to a one-month group and a three-month group. The one-month group receives an additional 150 baht of project funds if they deposit 100 baht of their money within one month of enrollment. The three-month group receives 150 baht for depositing 100 baht within three months of enrollment.~3. Each participant is paired with another study participant. If both quit, each receives a cash bonus of 1,200 baht. At enrollment, pairs receive brief counseling on ways to support each other during the quit attempt.
Study NCT01311115 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Smoking cessation education and counseling
Description: Participants receive educational pamphlets on reasons to quit smoking and strategies for quitting smoking. They also receive one-time, group counseling on quitting smoking from a nurse trained in smoking cessation counseling.
Study NCT01311115 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking cessation education and counseling
Description: Participants receive educational pamphlets on reasons to quit smoking and strategies for quitting smoking. They also receive one-time, group counseling on quitting smoking from a nurse trained in smoking cessation counseling.
Study NCT04091581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Systane Complete
Description: Systane Complete will be instilled and rate of evaporation assessed before and after.
Study NCT03300024 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Expanded polytetrafluoroethylene Graft
Description: Group will receive any standard ePTFE graft (control) based on the surgeons' discretion. The graft will be placed either in the arm (brachial artery to axillary vein) or forearm (brachial artery to cephalic or suitably sized vein) depending on which location works best in your particular case.
Study NCT03300024 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bovine Carotid Artery Graft
Description: Group will receive the BCA graft (experimental).The graft will be placed either in the arm (brachial artery to axillary vein) or forearm (brachial artery to cephalic or suitably sized vein) depending on which location works best in your particular case.
Study NCT03493451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Administered intravenously
Study NCT03424993 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Sodium Restriction
Description: A registered dietician will counsel participants to reduce daily habitual dietary salt intake below 2000mg over 4 weeks
Study NCT03424993 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control
Description: Participants will consume their routine habitual dietary sodium intake > 3400mg per day with regular pre determined check in phone calls from a registered dietician.
Study NCT03941873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitravatinib
Description: Administered orally as a capsule
Study NCT01705886 — intervention group
Intervention type: DEVICE
Intervention: RESTORIS Multicompartmental Knee System
Description: The RESTORIS Multicompartmental Knee (MCK) System components are intended for single or multicompartmental knee replacement used in conjunction with the MAKO® Robotic Arm Interactive Orthopedic System (RIO®). The components can be used for medial compartment, lateral compartment, patellofemoral compartment, or bicompartmental (medial and patellofemoral compartments) knee replacement. The device is intended to be used with bone cement.
Study NCT01705886 — intervention group
Intervention type: DEVICE
Intervention: Depuy Knee Replacement System
Description: The Depuy Knee Replacement System components are intended for use in total knee replacement. These components are intended for implantation with bone cement.
Study NCT01705886 — intervention group
Intervention type: DEVICE
Intervention: Stryker® Knee Replacement System
Description: The Stryker® Knee Replacement System components are intended for use in total knee replacement. These components are intended for implantation with bone cement.
Study NCT03842085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Humanized Bispecific Monoclonal Antibody MBS301
Description: The patients confirming to the eligibility criteria will be assigned to the 8 dose groups based on the sequence of inclusion. MBS301 will be administered intravenousely on day 1 of each 21-day cycle for each patient.The first intravenous infusion for each patient will be last for 90 minutes.It could be changed to 60 minutes for the subsequent infusions if the drug is well tolerated.
Study NCT03941873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Administered intravenously
Study NCT03947281 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Almond snack
Description: The almond intervention will be roasted, unsalted almonds provided at 56 g/day for 28 days. Almonds provide approximately 350 kcals/day.
Study NCT03947281 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cereal-based snack
Description: The cereal-based intervention will be a prepared mix of cereal, pretzels, and bread sticks prepared at the WHNRC. It will be provided at the level of 350 kcals per day for 28 days.
Study NCT04200794 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: musical instrumental training
Description: Learning to play a string instrument in a group setting (school class)
Study NCT04200794 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: sensitization to music
Description: sensitization to music via listening, theory, moderate practice on small percussive instruments and choir singing in a group setting (school class)
Study NCT00970723 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: high blood pressure treatment
Description: over one 14 month period: strongly recommended hygiene-dietetic measurements, complete assessment with ambulatory measurement of the blood pressure in D0, 3 and 12 months, a therapeutic strategy according to the results, and control every 3 months
Study NCT00970723 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: sleep apnea treatment
Description: over one 14 month period: complete assessment with night polysomnography in D0, 3 and 12 months, a therapeutic strategy according to the results, and control every 3 months
Study NCT00970723 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: diabetic macular edema treatment
Description: over one 14 month period: control every 3 months, treatments by laser (focal or grid) are authorized until 9 months, treatments by injections are authorized until 6 months
Study NCT00970723 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: diabetic macular edema treatment
Description: over one 14 month period: control every 3 months, treatments by laser (focal or grid) are authorized until 9 months, treatments by injections are authorized until 6 months
Study NCT01244230 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fexofenadine/Allegra (M016455)
Description: Pharmaceutical form:dry syrup formulation to be suspended in water~Route of administration: oral
Study NCT00039780 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BNP7787
Description: The treatment regimen administered in this study is a single IV doxe of paclitaxel (80 mg/m2) +/- Herceptin given over 1 hour and either BNP7787 (18.4 g/m2) or placebo given over 45 minutes each week. One treatment cycle = 8 weeks.
Study NCT00039780 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The treatment regimen administered in this study is a single IV doxe of paclitaxel (80 mg/m2) +/- Herceptin given over 1 hour and either BNP7787 (18.4 g/m2) or placebo given over 45 minutes each week. One treatment cycle = 8 weeks.
Study NCT02550249 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Intravenous administration of nivolumab
Study NCT04497688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-rhG-CSF
Description: Patients received a single dose of PEG-rhG-CSF per cycle. The chemotherapy regimen must meet the interval between two chemotherapy sessions at least 12 days.
Study NCT01815242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-Paclitaxel
Study NCT01815242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Study NCT01815242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Study NCT03357926 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: 24 hour Holter ECG Monitoring
Description: 24 hour Holter ECG Monitoring
Study NCT00809835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galantamine
Description: Daily 8 mg galantamine capsule
Study NCT00809835 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer Assisted Cognitive Behavioral Therapy (CBT)
Description: CBT a psychotherapeutic approach that addresses dysfunctional emotions, maladaptive behaviors and cognitive processes and contents through a number of goal-oriented, explicit systematic procedures. The name refers to behavior therapy, cognitive therapy, and to therapy based upon a combination of basic behavioral and cognitive principles and research.
Study NCT04050787 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: D2 Lymphadenectomy including No. 10
Description: After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy, Laparoscopic total gastrectomy with D2 lymphadenectomy including spleen-Preserving No. 10 Lymph Node Dissection will be performed with curative treated intent. The type of reconstruction will be selected according to the surgeon's experience and anastomotic procedure is performed extracorporeally using a mini-laparotomy
Study NCT04050787 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: D2 lymphadenectomy excluding No. 10
Description: After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy, Laparoscopic total gastrectomy with D2 lymphadenectomy excluding spleen-Preserving No. 10 Lymph Node Dissection will be performed with curative treated intent. The type of reconstruction will be selected according to the surgeon's experience and anastomotic procedure is performed extracorporeally using a mini-laparotomy
Study NCT03883347 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Intravenous administration of dexmedetomidine 0.6 mcg / kg within 10 minutes prior to regional anesthesia and 0.6 mcg / kg / h after performing regional anaesthesia until the end of the surgery
Study NCT03883347 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: Intravenous administration of remifentanil 1 mcg / kg within 10 minutes prior to regional anesthesia and 0.025 mcg / kg / h after performing regional anaesthesia until the end of the surgery
Study NCT03245242 — intervention group
Intervention type: OTHER
Intervention: Enhanced Recovery after Surgery
Description: Enhanced Recovery After Surgery (ERAS) protocol is a multi-disciplinary program that aims to standardize care processes around the pre-, intra-, and post-operative care setting. This group will prospectively receive care under a pre-defined protocol.
Study NCT03245242 — intervention group
Intervention type: OTHER
Intervention: Historical usual surgical care
Description: Recent historical controls will have received care under usual care that existed prior to implementation of an enhanced recovery protocol.
Study NCT02943928 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: traditional method by experience
Description: Operator inserted the double lumen tube by experience
Study NCT02695810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: 10 mg per day as monotherapy for 13 weeks
Study NCT03555591 — intervention group
Intervention type: DRUG
Intervention: Trelagliptin
Description: Trelagliptin tablets
Study NCT02695810 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: 2 x 850 mg per day as monotherapy for 13 weeks
Study NCT02695810 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Interval training, 5 times per week, 30 min per session
Study NCT03902886 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: gait analysis
Description: gait analysis using an optoelectronic system and a surface EMG
Study NCT03844386 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA.tHIVconsv3
Description: viral-vector, MVA, expressing immunogens derived from conserved yet immunogenic regions of HIV-1
Study NCT03980743 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: iOTA text messaging intervention
Description: Over 6 months, participants in the iOTA arm will have monthly in-person visits with a health coach who will work with the participant to set goals for the upcoming month related to healthy eating and activity. The participant will receive daily text message health tips related to their goals, and will be prompted once a week to respond with a text indicating their weight and how they are doing with their goals. Following the 6-month active treatment phase, participants will receive text messages only for another 3 months.
Study NCT03980743 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Health Education text messaging intervention
Description: Over 6 months, participants in the Health Ed arm will also have monthly in-person visits with a health coach who will provide education on energy balance and problem-solving. Specific goals will not be set, but the health coach will assist participants in problem-solving any challenges. Participants will receive a weekly automated motivational text message health tip from the study related to what they learned in their health coaching sessions. Following the 6-month active treatment phase, participants will receive text messages only for another 3 months.
Study NCT02417662 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radical Radiotherapy (Conventional RT and SABR)
Description: Radical radiotherapy (conventional or SABR) to primary and SABR to the metastases
Study NCT02417662 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-investigational SACT
Description: There is no intervention in the control group, patients will receive SACT. The choice of SACT is determined by the treating clinician and will be supplied from hospital commercial stock, and prepared and administered according to institutional guidelines.
Study NCT03987139 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Hypertension
Description: Hypertension is induced by an infusion of noradrenaline within acceptable limits Baseline recording (10 minutes) is performed. MAP gradually increases in steps of 5-10 mmHg during ongoing TCD. When the desired maximum MAP is reached, measurement is made at steady state (10 minutes).~Noradrenaline infusion is stopped. When MAP is stabilized, new baseline is measured for 10 minutes.
Study NCT03987139 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Hyper- and hypoxia
Description: The mechanical ventilator is adjusted to mild hypoxia, normoxia and mild hyperoxia. Measurements are made for 10 minutes at normoxia and after steady state is reached, respectively. hyperoxia and hypoxia. Oxygenation is controlled by arterial blood gas before and during steady state.
Study NCT03987139 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Hyper- and hypocapnia
Description: The mechanical ventilator is adjusted to a delta PaCO2 on the ventilator for both hypocapnia and hypercapnia. Measurements are made for 10 minutes at normocapnia and after steady state is reached, respectively. hyper- and hypocapnia.
Study NCT01140594 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Photorefractive keratectomy
Description: One eye undergoes wavefront-guided PRK with the Visx S4 CustomVue excimer laser.
Study NCT01140594 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laser in-situ keratomileusis
Description: One eye undergoes wavefront-guided LASIK using the Visx S4 excimer laser.
Study NCT03940846 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Virtual biopsy
Description: Radiomics -the high throughput extraction of quantitative features from medical imaging- extract features that might potentially decode biologic tumor information, which might ultimately reduce the need to use invasive procedure, such as tissue biopsy.
Study NCT04015817 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: paramedical and non-pharmacological services
Description: Paramedical and non-pharmacological services (work on positions, ventilatory education, use of a fan, pulmonary rehabilitation, stress management, mindfulness meditation, psychosocial services, possible support from the mobile palliative care team)
Study NCT02492191 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Smartphone app Recovery Assessment by Phone Points (RAPP)
Description: An e-assessed follow-up of day surgery patients postoperative recovery measured via smartphone app
Study NCT04193111 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: TMD pain screener
Description: The danish TMD pain screener is given to all participants
Study NCT01391689 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: diindolylmethane
Description: Given PO
Study NCT01391689 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given PO